Oral nucleoside/nucleotide analogs without hepatitis b immune globulin after liver transplantation for hepatitis b

American Journal of Gastroenterology

Volumn 108, Issue 6, 2013, Pages 942-948

  Fung, James ^a,b   Chan, See Ching ^a,b   Cheung, Cindy ^a   Yuen, Man Fung ^a,b   Chok, Kenneth Siu Ho ^a   Sharr, William ^a   Chan, Albert Chi Yan ^a   Cheung, Tan To ^a   Seto, Wai Kay ^a   Fan, Sheung Tat ^a,b   Lai, Ching Lung ^a,b   Lo, Chung Mau ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REINFECTION; SEROLOGY; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS LOAD;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SURVIVAL RATE; VIRAL LOAD; YOUNG ADULT;

EID: 84878940734     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.111     Document Type: Article

References (16)

1. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 ; 329 : 1842-7. (Pubitemid 23360483)
2. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and aft er liver transplantation for chronic hepatitis B. Hepatology 2001 ; 33 : 424-32. (Pubitemid 32119032)
3. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000 ; 70 : 809-15.
4. Lo CM, Cheung ST, Lai CL et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001 ; 233 : 276-81.
5. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 ; 348 : 1212-5. (Pubitemid 26361609)
6. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998 ; 28 : 585-9. (Pubitemid 28363690)
7. Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy aft er a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence aft er liver transplantation. J Hepatol 2003 ; 38 : 811-7. (Pubitemid 36613348)
8. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 ; 132 : 931-7. (Pubitemid 46440868)
9. Teperman L, Spivey J, Poordad F et al. Randomized trial of emtricitabine/tenofovir DF +/? HBIG withdrawal post-orthotopic liver transplantation for chronic hepatitis B: 48 week results. Liver Transpl 2011 ; 17 : S94.
10. Angus PW, Patterson SJ, Strasser SI et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008 ; 48 : 1460-6.
11. Fung J, Cheung C, Chan SC et al. Entecavir monotherapy is eff ective in suppressing hepatitis B virus aft er liver transplantation. Gastroenterology 2011 ; 141 : 1212-9.
12. Lo CM, Liu CL, Lau GK et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005 ; 11 : 807-13. (Pubitemid 40975583)
13. Angus PW, McCaughan GW, Gane EJ et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides eff ective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000 ; 6 : 429-33. (Pubitemid 30489114)
14. Lake JR, Shorr JS, Steff en BJ et al. Diff erential eff ects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005 ; 5 : 549-57. (Pubitemid 40313347)
15. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005 ; 11 : 402-9. (Pubitemid 40533208)
16. Faria LC, Gigou M, Roque-Afonso AM et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence aft er liver transplantation. Gastroenterology 2008 ; 134 : 1890-9, quiz 2155. (Pubitemid 351783254)